Squamous cell transformation and \textit{EGFR} T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report

ROSSELLA BRUNO$^{1*}$, AGNESE PROIETTI$^{2*}$, GRETA ALÌ$^2$, GIANFRANCO PUPPO$^3$, ALESSANDRO RIBECHINI$^4$, ANTONIO CHELLA$^3$ and GABRIELLA FONTANINI$^{1-5}$

$^1$Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa; $^2$Division of Pathological Anatomy; $^3$Division of Pneumology; $^4$Endoscopic Section of Pneumology; $^5$Program of Pleuropulmonary Pathology, University Hospital of Pisa, I-56100 Pisa, Italy

Received November 24, 2016; Accepted June 9, 2017

DOI: 10.3892/ol.2017.6913

\textbf{Abstract.} The present case report describes the infrequent coexistence of squamous cell transformation and the epidermal growth factor receptor (\textit{EGFR}) T790M mutation as resistance mechanisms to first line treatment with tyrosine kinase inhibitors. The patient was a 44-year-old female, diagnosed with a primitive advanced lung adenocarcinoma with bone metastases. The tumor was positive for the \textit{EGFR} exon 19 deletion, therefore the patient was treated with afatinib (40 mg/day, orally) and radiotherapy for bone lesions. After 16 months, the patient developed resistance. Cytological examination of the pleural effusion confirmed an adenocarcinoma positive for the \textit{EGFR} exon 19 deletion and the T790M mutation within exon 20, while a biopsy from the upper left bronchus revealed a keratinizing squamous cell carcinoma positive for the \textit{EGFR} exon 19 deletion. In addition, the \textit{EGFR} mutations were concomitantly detected in circulating cell-free tumour DNA. Due to the presence of the T790M mutation, the patient underwent osimertinib therapy (80 mg/day, orally), which resulted in a partial tumour regression at the 2-month follow-up, whereas the squamous lesions were treated with radiotherapy. The adenocarcinoma and squamous carcinoma components may share the same origin, according to the presence of the \textit{EGFR} exon 19 deletion in both lesions. More accurate characterization of resistance mechanisms may lead to the development of improved treatment regimens.

\textbf{Introduction}

A significant proportion (15-20\%) of patients with lung adenocarcinoma harbor epidermal growth factor receptor (\textit{EGFR}) activating mutations (1) and can benefit from first-line treatment with tyrosine kinase inhibitors (TKI), including gefitinib (2) or erlotinib (3) (first generation TKI) and afatinib (second generation TKI) (4). However, after 12-16 months of TKI treatment almost all patients develop acquired resistance and experience tumour progression (5,6).

The most common resistance mechanism, detectable in ~50\% of TKI resistant tumors, is the emergence of a secondary T790M mutation in exon 20 of \textit{EGFR} (5,7). Other well-known resistance mechanisms, in patients with non-small cell lung cancer treated with \textit{EGFR}-TKI, include the amplification of \textit{MET} proto-oncogene tyrosine kinase receptor (\textit{MET}) (20\%) (8), the development of small cell lung cancer transformation (14\%) (9,10) and the presence of acquired phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (\textit{PI3KCA}) mutations (5\%) (6). Less common resistance mechanisms (30\%) include the activation of Insulin-Like Growth Factor-1 Receptor (11), the epithelial to mesenchymal transition (12), and more rarely squamous cell transformation (13-16). Different resistance mechanisms may be observed in the same patient (6) due to intratumor and intrametastatic heterogeneity (17), which strongly influence the patient’s response to treatment.

The identification of molecular alterations responsible for acquired TKI resistance is crucial for patient management, as multiple novel treatment strategies are available to overcome this issue (18). For instance, in cases of T790M-mediated resistance, the use of a third-generation TKI, which irreversibly and selectively blocks T790M mutant clones, has been demonstrated to increase the potency of \textit{EGFR}-TK inhibition (19,20).

\textit{Correspondence to:} Professor Gabriella Fontanini, Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 57 Via Roma, I-56100 Pisa, Italy E-mail: gabriella.fontanini@med.unipi.it

\textit{*Contributed equally}

\textit{Key words:} lung adenocarcinoma, epidermal growth factor receptor, tyrosine kinase inhibitor, resistance mechanisms
A second tumour biopsy is recommended in case of TKI resistance; however, a single biopsy specimen may not mirror all the biological properties of a tumour. Combining re-biopsy analysis with molecular characterization of circulating cell-free tumour (ct) DNA represents a good strategy to describe the molecular landscape of a tumour (21-23). In addition, temporal changes to EGFR activating and resistance mutations in plasma DNA are directly linked to treatment efficacy (24,25).

In the present report the case of a patient who developed two resistance mechanisms in response to first-line afatinib, the T790M mutation and the rare squamous cell transformation, is described. To the best of our knowledge, only a few similar cases have previously been described and they focused on patients with lung adenocarcinoma who were treated with erlotinib and gefitinib (13-15).

Case report

Written informed consent for the publication of this report was obtained from the patient. In October 2014, a 44-year-old female with an 8 pack/year smoking history presented at the University Hospital of Pisa (Pisa, Italy) with back pain. A few weeks later the patient underwent magnetic resonance imaging of the vertebral column, which revealed a number of osteoblastic bone lesions (S1-3; D2-3 and D7-10 laminas). A computed tomography (CT) scan revealed a left lower lobe mass, and pleural and pericardial effusions (PE). The patient underwent endobronchial ultrasound biopsy and pleural fluid analyses. Histological and cytological samples examination identified an adenocarcinoma, further characterized using cell-block (stained with 10% buffered formalin at room temperature for 24 h) paraffin-embedded sections (thickness, 2 µm) by immunohistochemical staining using the ultraView Universal DAB Detection kit (Ventana Medical Systems, Inc., Tucson, AZ, USA), according to the manufacturer's protocol, with anti-thyroid transcription factor (TTF-1) antibody (mouse monoclonal primary antibody; clone 8G7G3/1; ready-to-use; catalog no. 790-438; Ventana Medical Systems, Inc.) for 44 min at 37˚C, which demonstrated a strong positive nuclear stain. An Olympus BX51 light microscope (Olympus Italia Srl; Segrate, Italy) was used for the analysis. The final diagnosis was adenocarcinoma (26), consistent with a lung primary cancer with bone metastases.

An extensive molecular analysis was performed on the PE. Fluorescent In Situ Hybridization (FISH) was performed to evaluate translocations of anaplastic lymphoma kinase (ALK) (using a Vysis ALK Dual-Color Break Apart FISH probe kit; Abbott Laboratories, Abbott Park, IL, USA), proto-oncogene tyrosine-protein kinase ROS (ROS1; using a ROS1 6q22 BreakProbe; Kreatech; Leica Microsystems, Ltd., Milton Keynes, UK) and RET proto-oncogene (RET; using a RET 10q11 BreakProbe; Kreatech; Leica Microsystems, Ltd.), and to assess the presence of MET amplification (Vysis MET Spectrum Red and CEP7 D7Z1 Spectrum Green; Abbott Laboratories). FISH analysis was performed according to the manufacturers'protocols. All FISH tests were negative: ALK, 4% of neoplastic rearranged cells (cut-off 15%); ROS1, 0% of neoplastic rearranged cells (cut-off 15%); RET, 5% of neoplastic rearranged cells (cut-off 15%); and MET, MET/CEP7=1.1 (cut-off ≥2).

Mutational analysis of KRAS, BRAF, NRAS, PIK3CA, ALK, ERBB2, DDR2, MAP2K1, EGFR, RET was performed using a Sequenom Mass-Array (matrix assisted laser desorption ionization-time of flight mass spectrometry) using the Myriad Lung Status kit (Diatech Pharmacogenetics SRL, Jesi, Italy) together with the analysis software MASSARRAY® TYPER 4.0 (Diatech Pharmacogenetics, Jesi SRL) according to the manufacturer's protocol (limit of detection: 2.5-5% for EGFR and 2.5-10% for all other genes). The PE demonstrated a deletion in EGFR exon 19 (ex19del).

In November 2014, the patient started treatment with afatinib (40 mg/day, orally). The bone lesions required a radio therapeutic approach due to nerve peduncle compression, therefore the patient received radiation (30 Gy in five fractions on S1-3; 25 Gy in five fractions on D7-10 and 30 Gy in five fractions on D2-3). In addition, the patient was treated with denosumab (120 mg every 28 days, intravenously). After 4 weeks of afatinib, a CT scan revealed a partial response in the lung mass, and a total response for the effusions and bone lesions.

The patient tolerated the therapy well, with mild diarrhea and post-actinic pneumonia, which was treated with antibiotics and anti-inflammatory therapy. Foci of post-actinic pneumonia were observed, primarily on paravertebral and medium lobe sites. At subsequent medical examinations, after 5, 7 and 9 months of treatment, the patient was stable and no EGFR mutations were detected on ctDNA from plasma collected at each visit (Fig. 1A). ctDNA was purified from 4 ml of plasma using a QIAmp Circulating Nucleic Acid kit (Qiagen, Inc., Valencia, CA, USA) and EGFR mutational analysis was performed using an Easy®EGFR Quantitative Real Time PCR kit (Diatech Pharmacogenetics SRL) according to the manufacturer's protocol. The Easy®EGFR quantitative Real Time PCR kit is validated for use on liquid biopsy and its limit of detection ranges from 0.5 to 2%.

In February 2016, a CT scan control detected an almost complete response on the primitive lung mass and bone lesions. The patient carried on the therapy with afatinib and denosumab. Three months later (May 2016), a CT scan demonstrated a large area of atelectasia of the upper left lung lobe partially involving the lower lobe with PE. The cytological examination of PE confirmed an adenocarcinoma with a positive immunohistochemical stain for TTF-1. Cytological samples from pleural effusion were positive for EGFR ex19del and T790M; both mutations were concomitantly detected in ctDNA (Fig. 1B). Broncoscopic investigation of the upper left bronchus revealed a partial obstruction and infiltration from a whitish neoformation. This lesion was biopsied. The obtained tissue was fixed in 10% buffered formalin (room temperature, 24 h), paraffin-embedded and cut into 5 µm thick sections. The hematoxylin-eosin stain (room temperature, 1 h 26 min) revealed a keratinizing squamous cell carcinoma confirmed by immunohistochemical examination, performed as aforementioned, using a p40 antibody (mouse monoclonal primary antibody; clone BC28; ready-to-use; catalog no. 790-4950; Ventana Medical System, Tucson, AZ, USA) for 40 min at 42˚C, the results of which were strongly positive, and for TTF-1 antibody, the result of which was negative. The two lesions harboured the ex19del mutation. The same FISH and mutational tests as those executed on pre-TKI...
specimen were performed on the post-TKI adenocarcinoma and squamous cell carcinoma samples. Again, all FISH tests gave negative results: ALK, 0% of neoplastic rearranged cells; ROS1, 0% of neoplastic rearranged cells; RET, 0% of neoplastic rearranged cells; and MET, MET/CEP7=1 in the adenocarcinoma. In the squamous cell carcinoma: ALK, 2% of neoplastic rearranged cells; ROS1, 0% of neoplastic rearranged cells; RET, 0% of neoplastic rearranged cells; and MET, MET/CEP7=1. In addition, HER2 amplification (Vysis HER-2/neu SpectrumOrange/CEP17 SpectrumGreen Probes; Abbott Laboratories) was evaluated in post-TKI samples, for which the results were negative: HER2/CEP17=0.9 (cut-off ≥2) in the adenocarcinoma, HER2/CEP17=1 (cut-off ≥2) in the squamous cell carcinoma.

The patient underwent osimertinib (80 mg/day, orally) therapy and radiotherapy for squamous lesions. At a 2-month follow-up T790M positive lesions exhibited a partial regression. Fig. 2 presents the patient's CT-images and histological examinations, and Fig. 3 presents the patient's clinical response.

Discussion

Patients with EGFR mutant lung adenocarcinoma treated with TKI typically develop resistance within 1 year of treatment (5). The existence of different acquired TKI resistance mechanisms together with tumour heterogeneity constitutes a major challenge for clinical practice (6).

The present report describes the case of a patient with lung adenocarcinoma treated with afatinib who developed the T790M mutation and squamous cell transformation. To date, only a few cases of squamous cell transformation, with (13,15) and without (14) concomitant T790M, have been reported in response to erlotinib and gefitinib, and no similar cases have been reported in response to afatinib (27). Longo et al (16) recently reported a case of lung cell adenocarcinoma positive for the EGFR exon 21 L858R mutation, who, following TKI treatment, developed squamous cell carcinoma change together with an EGFR exon 20 S768I secondary mutation.

In our case, histological transformation may have been a consequence of TKI treatment or it could have been enhanced by radiotherapy, as reported in other types of cancer, including prostate cancer (28).

All the histological evaluations have been performed on specimens obtained by needle biopsy, and although there were different morphological and immunohistochemical characteristics in pre and post-TKI lesions, the presence of the squamous cell carcinoma prior to EGFR-TKI therapy in form of an adenosquamous carcinoma cannot be excluded. However, lung adenocarcinoma exhibits a different molecular landscape compared with squamous cell carcinoma, for instance EGFR mutations are present in 10-40% of cases of adenocarcinoma, but rarely in squamous cell carcinoma (29). The presence of ex19del in both lesions in the present study suggests that the adenocarcinoma and squamous carcinoma components share the same clonal origin and a mixed tumour is unlikely on the basis of the different location of the two lesions. Furthermore, all the tumour lesions were extensively characterized from a molecular point of view and the only difference was the presence of the T790M mutation, which was detected only in the post-TKI adenocarcinoma specimen.

The reported case highlights the role of intra-tumour heterogeneity, defined as the presence within the same
tumour of distinct cellular populations with specific phenotypic features, in response to TKI treatment, which selects clones with intrinsic or acquired resistance that drive disease progression (30-32). However, a complete characterization of the mechanisms of response and resistance is essential to provide patients with the greatest clinical benefit and several studies and case reports confirm this issue (5,6,9,10,13-16,18).

In the present context, a single tumour biopsy, limited by the presence of geographic heterogeneity, may be inadequate to detect all cancer gene mutations, explaining the lack of a direct correlation between molecular alteration and clinical efficacy of treatment (23). The liquid biopsy and analysis of ctDNA furthers understanding of intra-tumour heterogeneity, since it detects contributions from multiple tumour sites. In the present case report, as soon as the patient experienced clinical progression, activating and resistance mutations became detectable on ctDNA, supporting its value in agreement with previously published data (24,25).

However, according to current knowledge and reported cases, neither liquid biopsy nor solid biopsy on their own can suffice for the monitoring of cancer therapy. In spite of the non-invasiveness of liquid biopsy and its high informative value, resistance mechanisms, including phenotypic changes, cannot be evaluated...
without a histopathological analysis of tumour tissues; for this reason tissue biopsy should be performed whenever possible.

In conclusion, the present case report underlines the complementarity of tumour re-biopsies and analysis of ctDNA in order to have a more complete view of temporal evolution and molecular diversity of TKI-resistant disease, thus improving therapeutic regimens.

References

1. Ileana EE, Wistuba II and Izzo JG: From uniplex to multiplex molecular profiling in advanced non-small cell lung carcinoma. Cancer J 21: 413-424, 2015.

2. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.

3. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Fuentealba A, Quintana F, Perez-Cordon MM, Matheu E, et al: Sorafenib or chemotherapy for patients with advanced hepatocellular carcinoma: A randomised phase 3 study. Lancet Oncol 13: 1133-1142, 2012.

4. Yang JC, Wu YL, Schiller JH, Ford JC, Rosell R, Hall CB, Chen E, Kanai Y, Jhiang S, et al: Gefitinib or placebo for initial treatment of stage IV East Asian lung adenocarcinoma. N Engl J Med 362: 2120-2129, 2010.

5. Pao W, Kris MG, Miller VA, Ladanyi M and Miller VA: Gefitinib or chemotherapy for non-small-cell lung cancer with EGFR mutation-positive disease. N Engl J Med 352: 2129-2141, 2005.

6. Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Rosell R, Carcereny E, Gervais R, Vergnenegre A, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with EGFR mutation-positive disease. N Engl J Med 352: 2119-2129, 2005.

7. Schiller JH, Harrington D, Belani CP,ig, Sandler A, Eisenhauer EA, Tebbutt NC, Thurlow M, et al: Updated results of phase III trial 9751 (E1594) of cisplatin-based chemotherapy for EGFR mutation-positive non-small-cell lung cancer (EURTAC): A randomised, open-label, phase 3 trial. Lancet Oncol 13: 239-248, 2012.

8. Li Y, Song Z, Jing Y, Tang Z, Kang J and Ma X: Novel selective and potent EGFR inhibitor that overcomes T790M-mediated resistance in non-small cell lung cancer. Molecules 21: pii: E1462, 2016.

9. Cross SA, Doi S, Sano T, Ohashi K, Ahmad N, Fujiwara S, Soussi T, Scott K, Goldie JH, et al: T790M mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.

10. Chabon JJ, Smirnov AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurz DM, Stehr H, Scherer F, Karlovich CA, et al: Tracking tumor DNA circulating tumor cell DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7: 11815, 2016.

11. Pao W, Politi KA, Riely GJ, Zakowski MF, Ladanyi M and Riely GJ: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 135 patients with EGFR-mutant lung cancer: Implications for the development of novel agents. Clin Cancer Res 19: 2240-2247, 2013.

12. Parikh P, Chabon JJ, Hedley DW, Townsend B, Miller VA, Reuter V and Scher HI: Primary squamous cell carcinoma transformation and the T790M mutation: A case report of a distinct, acquired drug resistance mechanisms in epithelial growth factor receptor-mutant lung adenocarcinoma: Small cell lung cancer transformation and the T790M mutation. Intern Med 54: 2491-2496, 2015.

13. Ali G, Bruno R, Giordano M, Prediletto I, Marconi L, Zupo S, Fedeli F, Ribechni A, Chella A and Fontanini G: Small-cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma. Oncol Lett 12: 4009-4012, 2016.

14. Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Iouze M, Brenner R, Kato Y, Mascaux C and Hirsch FR: Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Oncol Rep 36: 277-288, 2015.

15. Thomson S, Buck E, Petti F, Grifin G, Brown E, Ramnarine N, Iwata K, Gibson N and Hadey JD: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung cancer cell lines and xenografts to epithelial growth factor receptor inhibition. Cancer Res 65: 9455-9462, 2005.

16. Scher KS, Saldivar JS, Fishbein M, Marchevsky A and Reckamp KL: EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung. J Natl Compr Canc Netw 11: 1040-1044, 2013.

17. Levin PA, Mayer M, Hoskin S, Sailors J, Oliver DH and Gerber DE: Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition. J Thorac Oncol 11: 362-368, 2016.

18. Jukna A, Montanari G, Mengoli MC, Cavazza A, Covi M, Barbieri F, Bertolino F and Rossi G: Squamous cell carcinoma ‘transformation’ concurrent with secondary T790M mutation in resistant EGFR-mutated adenocarcinomas. J Thorac Oncol 11: 1079-1086, 2016.

19. Longo L, Mengoli MC, Bettelli S, Manfredini S and Rossi G: Synchronous occurrence of squamous cell carcinoma ‘transformation’ and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma. Lung Cancer 103: 24-26, 2017.

20. Jamal-Hanjani M, Quezada SA, Larkin J and Swanton C: Translational implications of tumor heterogeneity. Clin Cancer Res 21: 1258-1266, 2015.

21. Piotrowska Z and Sequist LV: Epidermal growth factor receptor-mutant lung cancer: New drugs, New resistance mechanisms, and future treatment options. Cancer J 21: 371-347, 2015.